
CLAIMS

What is claimed is:

1. A compound of Formula I or pharmaceutically acceptable salts thereof:



Formula I ;

wherein R_1 is isopropenyl or isopropyl;

X is selected from the group of C_{4-8} cycloalkyl, C_{4-8} cycloalkenyl, C_{4-9} spirocycloalkyl, C_{4-9} spirocycloalkenyl, C_{4-8} oxacycloalkyl, C_{4-8} dioxacycloalkyl, C_{6-8} oxacycloalkenyl, C_{6-8} dioxacycloalkenyl, C_6 cyclodialkenyl, C_6 oxacyclodialkenyl, C_{6-9} oxaspirocycloalkyl and C_{6-9} oxaspirocycloalkenyl ring,
wherein X is substituted with A, and wherein A is -C_{1-6} alkyl-halo;


Y is selected from the group of –$COOR_2$, -$C(O)NR_2SO_2R_3$, - $C(O)NHSO_2NR_2R_2$, -$NR_2SO_2R_2$, -$SO_2NR_2R_2$, -C_{3-6} cycloalkyl-$COOR_2$, -C_{2-6} alkenyl-$COOR_2$, -C_{2-6} alkynyl-$COOR_2$, -C_{1-6} alkyl-$COOR_2$, -alkylsubstituted C_{1-6} alkyl, -CF_2-$COOR_2$, -$NHC(O)(CH_2)_n$-$COOR_2$, -$SO_2NR_2C(O)R_2$, -tetrazole, and -CONHOH,
wherein n = 1-6;

R_2 is -H, -C_{1-6} alkyl, -alkylsubstituted C_{1-6} alkyl or-arylsubstituted C_{1-6} alkyl;

W is absent, or is -CH_2 or -CO;

R_3 is –H, -C_{1-6} alkyl or -alkylsubstituted C_{1-6} alkyl;

R_4 is selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} alkyl-C_{3-6} cycloalkyl, -C_{1-6} substituted -C_{1-6} alkyl, -C_{1-6} alkyl-Q_1, -C_{1-6} alkyl-C_{3-6} cycloalkyl-Q_1, aryl, heteroaryl, substituted heteroaryl, -COR_6, -SO_2R_7, -$SO_2NR_2R_2$, and



wherein G is selected from the group of –O-, -SO_2- and -NR_{12};

wherein Q_1 is selected from the group of -C_{1-6} alkyl, - C_{1-6} fluoroalkyl, heteroaryl, substituted heteroaryl, halogen, -CF_3, -OR_2, -$COOR_2$, -NR_8R_9, -$CONR_8R_9$ and -SO_2R_7;

R_5 is selected from the group of -H, -C_{1-6} alkyl, -C_{3-6} cycloalkyl, -C_{1-6} alkylsubstituted alkyl, -C_{1-6} alkyl-NR_8R_9, -COR_6, -SO_2R_7 and -$SO_2NR_2R_2$;

with the proviso that R_4 or R_5 cannot be -COR_6 when W is -CO;

with the further proviso that only one of R_4 or R_5 can be selected from the group of -COR_6, -SO_2R_7 and -$SO_2NR_2R_2$;

or when W is absent or is -CH_2, then R_4 and R_5 can be taken together with the adjacent N to form



;


R_6 is selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} alkyl-substitutedalkyl, -C_{3-6} cycloalkyl, -C_{3-6} substitutedcycloalkyl-Q_2, -C_{1-6} alkyl-Q_2, -C_{1-6} alkyl-substitutedalkyl-Q_2, -C_{3-6} cycloalkyl-Q_2, aryl-Q_2, -$NR_{13}R_{14}$, and -OR_{15};

wherein Q_2 is selected from the group of aryl, heteroaryl, substituted heteroaryl, -OR_2, -$COOR_2$, -NR_8R_9, SO_2R_7, -$CONHSO_2R_3$, and -$CONHSO_2NR_2R_2$;

R_7 is selected from the group of –H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, -C_{3-6} cycloalkyl, -CF_3, aryl, and heteroaryl;

R_8 and R_9 are independently selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, -C_{1-6} alkyl-Q_2, and -$COOR_3$,

or R_8 and R_9 are taken together with the adjacent N to form a cycle selected from the group of:



M is selected from the group of –R_{15}, -SO_2R_2, -$SO_2NR_2R_2$, -OH and –NR_2R_{12};

V is selected from the group of –$CR_{10}R_{11}$-, -SO_2-, -O- and –NR_{12}-;

with the proviso that only one of R_8 or R_9 can be -$COOR_3$;


R_{10} and R_{11} are independently selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl and -C_{3-6} cycloalkyl;

9. The compound as claimed in claim 8, wherein A is methyl-fluoro.

10. The compound as claimed in claim 1, wherein Y is $-COOR_2$.

11. The compound as claimed in claim 10, wherein Y is –COOH.


12. A compound or pharmaceutically acceptable salts thereof, wherein the compound is selected from the group of:



13. A pharmaceutical composition which comprises one or more of the compounds as claimed in claim 1, together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

14. A pharmaceutical composition which comprises one or more of the compounds as claimed in claim 12, together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

15. A pharmaceutical composition which comprises the compound




, together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

16. The pharmaceutical composition of claim 14 for use in treating infection by HIV, which additionally comprises an AIDS treatment agent selected from the group consisting of: (a) an AIDS antiviral agent; (b) an anti-infective agent; (c) an immunomodulator; and (d) an HIV entry inhibitor.


17. Use of an antiviral effective amount of a compound as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents in the manufacture of a medicament for treating a mammal infected with the HIV virus.

18. An intermediate compound which is selected from the group of:




, and .


19. A compound or pharmaceutically acceptable salts thereof, wherein the compound is selected from the group of:




,




,




,




,




,




,




Isomer 1 or Isomer 2,




,




,




,




,




,




,




,




Isomer A or Isomer B,



Isomer A or Isomer B,




,



,

22. A compound of Formula I or pharmaceutically acceptable salts thereof:



Formula I ;

wherein R_1 is isopropenyl or isopropyl;

X is selected from the group of C_{4-8} cycloalkyl, C_{4-8} cycloalkenyl, C_{4-9} spirocycloalkyl, C_{4-9} spirocycloalkenyl, C_{4-8} oxacycloalkyl, C_{4-8} dioxacycloalkyl, C_{6-8} oxacycloalkenyl, C_{6-8} dioxacycloalkenyl, C_6 cyclodialkenyl, C_6 oxacyclodialkenyl, C_{6-9} oxaspirocycloalkyl and C_{6-9} oxaspirocycloalkenyl ring,

wherein X is substituted with A, wherein A is -C_{1-6} alkyl-halo;


Y is selected from the group of –$COOR_2$, -$C(O)NR_2SO_2R_3$, -$C(O)NHSO_2NR_2R_2$, -$NR_2SO_2R_2$, -$SO_2NR_2R_2$, -C_{3-6} cycloalkyl-$COOR_2$, -C_{2-6} alkenyl-$COOR_2$, -C_{2-6} alkynyl-$COOR_2$, -C_{1-6} alkyl-$COOR_2$, -alkylsubstituted C_{1-6} alkyl, CF_2-$COOR_2$, -$NHC(O)(CH_2)_n$-$COOR_2$, -$SO_2NR_2C(O)R_2$,-tetrazole, and -CONHOH,
wherein n=1-6;

R_2 is -H, -C_{1-6} alkyl, -alkylsubstituted C_{1-6} alkyl or -arylsubstituted C_{1-6} alkyl;

W is absent, CH_2 or CO;

R_3 is -C_{1-6} alkyl or -alkylsubstituted C_{1-6} alkyl;

R_4 is selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} alkyl-$C(OR_3)_2$-C_{3-6} cycloalkyl, -C_{1-6} substituted alkyl, -C_{1-6} alkyl-C_{3-6} cycloalkyl, -C_{1-6} alkyl-Q_1, -C_{1-6} alkyl-C_{3-6} cycloalkyl-Q_1, aryl, heteroaryl, substituted heteroaryl, -COR_6, -$COCOR_6$, -SO_2R_7, -$SO_2NR_2R_2$,




, and ,

R_{15} is selected from the group of -C_{1-6} alkyl, -C_{3-6} cycloalkyl, -C_{1-6} substituted alkyl, -C_{1-6} alkyl-Q_3, -C_{1-6} alkyl-C_{3-6} cycloalkyl-Q_3 and -C_{1-6} substituted alkyl-Q_3;

R_{16} is selected from the group of -H, -C_{1-6} alkyl, -NR_2R_2, and -$COOR_3$;


R_{17} is selected from the group of -H, -C_{1-6} alkyl, -$COOR_3$, and aryl;

R_{20} and R_{21} are independently selected from the group of -H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, -C_{1-6} substituted alkyl-OR_2, and -COR_3,
or R_{20} and R_{21} are taken together with the adjacent N to form a cycle selected from the group of



with the proviso that only one of R_{20} or R_{21} can be -COR_3;

R_{22} and R_{23} are independently selected from the group of H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, and -C_{1-6} cycloalkyl,
or R_{22} and R_{23} are taken together with the adjacent N to form a cycle selected from the group of



R_{24} and R_{25} are independently from the group of H, -C_{1-6} alkyl, -C_{1-6} substituted alkyl, -C_{1-6} alkyl-Q_5, -C_{1-6} cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl; and

Q_5 is selected from the group of halogen and SO_2R_3.